You are here: Industry Insights > JAK

News List

Government increases JAK storeowners’ incentive from Rs 2.50 lakhs to up to Rs 5 lakhs expresspharma
August 09, 2021
As on 2nd August, 2021, the government has opened 8,001 Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP).
Topical JAK inhibitors becoming a major force in atopic dermatitis space: GlobalData expresspharma
July 05, 2021
An increasing number of JAK agents are filling the early and late-stage pipeline. Of the 98 pipeline agents, eight are JAKs – with six of these being topical formulations.
Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program worldpharmanews
December 24, 2019
Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. and Pfizer Inc. announced that the companies have entered into a global license agreement for ...
FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis drugs
August 19, 2019
AbbVie, a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor...
Sierra’s Momelotinib Granted FDA Fast Track Designation contractpharma
June 20, 2019
Underscores potential for momelotinib to address unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK inhibitor.
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key fiercebiotech
July 09, 2018
Gilead Sciences is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib in the next few weeks that could be an antidote for the biotech’s hepatitis C hangover.
AbbVie preps JAK atopic dermatitis candidate for phase 3 fiercebiotech
September 11, 2017
GlobalData has predicted that new therapies will help boost the atopic dermatitis market from $3.6 billion in 2014 to $7.3 billion in 2024.